Global Bioenergies said that if successful, the technology will be ready to take up mandated and targeted SAF volumes from 2030 and beyond.
“Following our ASTM certification during the summer 2023, we have teamed up with a large industrialist who had identified a perfect match between their technology and Global Bioenergies’. The combination of both technologies would result in a process overcoming the two major barriers for SAF production: capex and opex costs,” said Marc Delcourt, co-founder and CEO of Global Bioenergies.
Read the full article here.